Investors are worried about whether the prospects for privatization will change. There're rumors Fosun Pharma may have encountered funding issues. Slow Pre-Condition approval process is also a concern
What is covered in the Full Insight:
Overview of 24Q3 Results
Fosun Pharma's Financial Health
Privatization Overview and Challenges
Potential Risks and Concerns
Future Outlook
Boomeranged on Mon, 25 Nov 2024 08:50
The Offeror has received the approval from NDRC and will continue to liaise with local authorities of MOC and prepare for the registration filing with SAFE. Despite some progress, the overall approval process for Pre-Conditions is still slower than expected. Due to Chinese New Year holiday, it's already good to complete Pre-Conditions in 25Q1. Investors are hardly entirely reassured by a long wait
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.